首页> 外文期刊>Peptides: An International Journal >The cardiovascular effects of a chimeric opioid peptide based on morphiceptin and PFRTic-NH2
【24h】

The cardiovascular effects of a chimeric opioid peptide based on morphiceptin and PFRTic-NH2

机译:基于吗啡肽和PFRTic-NH2的嵌合阿片肽的心血管作用

获取原文
获取原文并翻译 | 示例
           

摘要

MCRT (YPFPFRTic-NH2) is a chimeric opioid peptide based on morphiceptin and PFRTic-NH2. In order to assess the cardiovascular effect of MCRT, it was administered by intravenous (i.v.) injection targeting at the peripheral nervous system and by intracerebroventricular (i.c.v.) injection targeting at the central nervous system. Naloxone and l-NAME were injected before MCRT to investigate possible interactions with MCRT. Results show that administration of MCRT by i.v. or i.c.v. injection could induce bradycardia and decrease in mean arterial pressure (MAP) at a greater degree than that with morphiceptin and PFRTic-NH2. When MCRT and NPFF were coinjected, we observed a dose-dependent weakening of these cardiovascular effects by MCRT. Because naloxone completely abolished the cardiovascular effects of MCRT, we conclude that opioid receptors are involved in regulating the MAP of MCRT regardless of modes of injection. The effect of MCRT on heart rate is completely dependent on opioid receptors when MCRT was administered by i.c.v. instead of i.v. The central nitric oxide (NO) pathway is involved in regulating blood pressure by MCRT under both modes of injection, but the peripheral NO pathway had no effect on lowering blood pressure mediated by MCRT when it was administered by i.c.v. Based on the results from different modes of injection, the regulation of heart rate by MCRT mainly involves in the central NO pathway. Lastly, we observed that the cardiovascular effects of MCRT such as bradycardia and decrease of blood pressure, were stronger than that of its parent peptides. Opioid receptors and the NO pathway are involved in the cardiovascular regulation by MCRT, and their degree of involvement differs between intravenous and intracerebroventricular injection. ? 2012 Elsevier Inc.
机译:MCRT(YPFPFRTic-NH2)是基于吗啡肽和PFRTic-NH2的嵌合阿片肽。为了评估MCRT的心血管作用,可通过针对周围神经系统的静脉内(i.v.)注射和针对中枢神经系统的脑室内(i.c.v.)注射来进行治疗。在MCRT之前注射纳洛酮和l-NAME,以研究与MCRT的可能相互作用。结果表明通过i.v.或i.c.v.与吗啡肽和PFRTic-NH2相比,注射可引起心动过缓,平均动脉压(MAP)降低程度更大。当同时注射MCRT和NPFF时,我们观察到MCRT对这些心血管作用的剂量依赖性减弱。由于纳洛酮完全消除了MCRT的心血管作用,因此我们得出结论,无论注射方式如何,阿片受体均参与调节MCRT的MAP。当i.c.v.给予MCRT时,MCRT对心率的影响完全取决于阿片受体。而不是i.v.在两种注射方式下,中央一氧化氮(NO)通路均通过MCRT调节血压,但在静脉内给药时,外围NO通路对降低MCRT介导的血压没有影响。根据不同注射方式的结果,MCRT对心率的调节主要涉及中枢NO途径。最后,我们观察到MCRT对心血管的影响(如心动过缓和血压降低)比其母体肽更强。阿片类药物受体和NO途径通过MCRT参与心血管调节,静脉和脑室内注射的程度不同。 ? 2012爱思唯尔公司

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号